Introduction
Glioblastoma multoforme (GBM) is the most frequent and aggressive primary malignant brain tumor in adults, with a median overall survival (OS) between 10 and 20 months [1] . The vast majority of patients with GBM experience recurrent disease, with a median time to recurrence of 7 months [2] . Surgery, temozolomide (TMZ), and fractionated radiotherapy are standards of care for newly diagnosed GBM [3] . However, the approach for GBM recurrence is considerably more heterogenous [4] . Options include repeated surgery, chemotherapy, bevacizumab (BEV), experimental agents, or re-irradiation. Numerous re-irradiation strategies exist, including conventional fractionated external beam radiotherapy (EBRT), fractionated stereotactic radiotherapy, hypo-fractionated stereotactic radiotherapy, high dose rate (HDR) brachytherapy, high dose rate (HDR) brachytherapy, low dose rate (LDR) brachytherapy, or stereotactic radiosurgery (SRS). Despite numerous options, median survival post-recurrence remains poor at 9-20 months [5] . The poor prognosis can be attributed to unique treatment limitations, which include the infiltrative nature of tumor cells, failure of anti-glioma drugs to cross the blood-brain barrier, tumor heterogeneity and the highly metastatic and angiogenic nature of the tumor making cells resistant to chemotherapy. Combination therapy approach is being developed against glioblastoma with new innovative combination drug regimens being tested in preclinical and clinical trials [6] . Despite the higher risk of distant brain lesions or subependymal spread, almost all patients develop tumor recurrence within or adjacent to the primary tumor bed [7] . Even though gliomas are infiltrative with ill-defined margins, SRS has been reported to be an effective treatment modality [8] [9] [10] [11] .
The aim of our study to assess the efficacy and toxicity of combination therapy approach using SRS and systemic treatment (chemotherapy (ТMZ) and antiangiogenic therapy (BEV)) in recurrent GBM treatment.
Methods
We retrospectively reviewed 21 patients (pts) who were treated for GBM recurrence at the State Institution "Institute of Neurosurgery named after acad. A.P. Romodanov of NAMS of Ukraine" (Kiyv, Ukraine) from January 2014 till March 2018. This study was approved by local Ethics Committee. We included 8 females and 11 men with pathologically confirmed GBM who received comprehensive initial treatment and combination of SRS and systemic treatment for GBM recurrence. Median age at time of diagnosis was 52.4 (29.7-69.3) years. The initial surgical treatment as gross total tumor resection was performed in 12 pts (57.1 %), subtotal resection -5 pts (23.8 %), biopsy -4 pts (19 %). Tumor MGMT promoter methylation was seen in 12 pts (57.1 %). In all cases adjuvant radiation therapy (60 Gy in 30 fractions) was used, 12 pts of them (57.1 %) -in combination with concurrent TMZ followed by 6-12 courses of TMZ according R. Stupp protocol [3] . Patient's demographic and clinical data were collected in Table 1 .
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(5-10 mm) around the contrast-enhancing target. The median Planning Target Volume (PTV) was 13.5 cm 3 (range: 3.9-40.7 cm 3 ). Seventeen (81 %) targets were located at the edge of the previous tumor resection cavity or at the area of previous biopsy.
Systemic treatment was applied after SRS (intravenous BEV 10-12 mg/kg once in 3 weeks up to 6 times; TMZ 150-200 mg/m² PO for 5 days, then 23-treatment free days until progression). 
Results
Retrospective analysis of outcomes revealed median survival after initial diagnosis of 18.3 months, and 1-and 2-year survival rates of 85.7 % (18 from 21 pts) and 38.1 % (8 from 21 pts) respectively. The median survival from the time of recurrence was 8.3 months.
The 6-and 12-months overall survival from SRS were 95.2 % (20 from 21 pts) and 23.8 % (5 from 21 pts), respectively.
Adverse radiation effects were noted in 6 (28.6 %) pts and were controlled with corticosteroids.
Adverse events grade 1-2 related to the systemic therapy included hematological complications, fatigue, hypertension and proteinuria were observed in 23.8 % (5 from 21 pts) without the occurrence of grade 3 events.
Survival and adverse events are represented in Table 2 . 
Discussion
GBM is an aggressive fatal disease with dismal median overall survival of 10 to 20 months. Even despite multimodality therapy and favorable pathologic features the vast majority of patients will recur in 6-8 months [10, 12] . Recurrence leads to progressive neurocognitive impairment and death in 3 to 9 months regardless re-operation [13, 14] . Current options for recurrence therapy are as follows: surgery, systemic therapy and re-irradiation. Combination therapy is an option for recurrence GBM recently being tested by some investigators [15, 16] . Our experience is consistent with latter and shows increase in survival rates with appropriate toxicity compared to other approaches as described in the current literature. We report a median survival from the time of recurrence 8.3 months and the 6-and 12-months overall survival from recurrence 95.2 % (20 from 21 pts) and 23.8 % (5 from 21 pts), respectively. The weak points of our study are an absence of direct comparison with the control group, low number of patients included and lack of tumor molecular data.
Recurrent GBM management using combination of SRS, chemotherapy and antiangiogenic therapy is a promising multimodal treatment approach providing survival improving whereas appropriate toxicity ratio. Further studies of combined treatment of GBM relapse are needed.
